Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted ...

Retrieved on: 2021-02-08 14:37:30

Tags for this article:

Medical specialties

Branches of biology

Stem cells

Clinical medicine

Transplantation medicine

Hematology

Surgical oncology

Hematopoietic stem cell transplantation

Lymphology

Acute myeloid leukemia

Myelodysplastic syndrome

Cell therapy

Jasper Therapeutics Inc.

Click the tags to see associated articles and topics

Jasper Therapeutics Announces Positive Data from Phase 1 Clinical Trial of JSP191 as Targeted .... View article details on HISWAI: https://pipelinereview.com/index.php/2021020877368/Antibodies/Jasper-Therapeutics-Announces-Positive-Data-from-Phase-1-Clinical-Trial-of-JSP191-as-Targeted-Stem-Cell-Conditioning-Agent-in-Patients-with-Myelodysplastic-Syndromes-or-Acute.html

Excerpt

... a first-in-class anti-CD117 (stem cell factor receptor) monoclonal antibody, ... We are evaluating JSP191, the only antibody of its kind, in two ongoing ...

Article found on: pipelinereview.com

View Original Article